既往含氮双膦酸盐治疗与COVID-19阳性患者结局的关联
这项在4个学术医疗中心开展的回顾性纵向研究纳入76,223例50岁以上COVID-19患者,其中1,853例既往处方含氮双膦酸盐(N-BP),559例使用唑来膦酸。经倾向性评分1:1匹配后,既往N-BP使用与15天、30天、180天复合结局(ICU入住、呼吸机使用或死亡)均无显著差异;唑来膦酸与口服N-BP相比亦无显著差异。
要点
- 既往N-BP使用与COVID-19老年患者15天、30天、180天复合结局无显著差异。
- 唑来膦酸与口服N-BP相比,结局无显著差异。
- 研究未显示N-BP对ICU入住、呼吸机使用或死亡有获益。
核心结论
- 在老年COVID-19患者中,既往暴露于含氮双膦酸盐包括唑来膦酸与ICU入住、呼吸机使用或死亡的减少无关。
研究设计与样本
- 回顾性纵向研究,基于PCORnet通用数据模型,覆盖4个学术医疗中心,数据截至2021年9月1日。
- 纳入年龄>50岁且诊断为COVID-19的个体,共识别76,223例,其中1,853例既往处方N-BP,559例处方唑来膦酸。
- N-BP使用定义为既往3年内处方;采用倾向性评分1:1匹配N-BP使用者与无既往N-BP使用者。
- 复合结局包括COVID-19诊断后15天、30天和180天内的ICU入住、呼吸机使用或死亡。
主要发现
- 匹配后,与未处方N-BP者相比,处方N-BP者在15天复合结局HR 1.22(95% CI: 0.89-1.67)、30天HR 1.24(95% CI: 0.93-1.66)、180天HR 1.17(95% CI: 0.93-1.48)均无显著差异。
- 与处方口服N-BP者相比,处方唑来膦酸者的结局无显著差异。
关键数值与推荐
- N-BP使用定义为COVID-19诊断前3年内有处方记录。
- 复合结局为COVID-19诊断后15天、30天或180天内ICU入住、呼吸机使用或死亡。
- ICU入住和呼吸机使用通过行政代码确定;死亡包括院内和院外事件。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: COVID-19 infection has resulted in significant morbidity and mortality globally, especially among older adults. Repurposed drugs have demonstrated activity in respiratory illnesses, including nitrogen-containing bisphosphonates. In this retrospective longitudinal study at 4 academic medical centers, we show no benefit of nitrogen-containing bisphosphonates regarding ICU admission, ventilator use, and mortality among older adults with COVID-19 infection. We specifically evaluated the intravenous bisphosphonate zoledronic acid and found no difference compared to oral bisphosphonates. BACKGROUND: Widely used in osteoporosis treatment, nitrogen-containing bisphosphonates (N-BP) have been associated with reduced mortality and morbidity among older adults. Based on prior studies, we hypothesized that prior treatment with N-BP might reduce intensive care unit (ICU) admission, ventilator use, and death among older adults diagnosed with COVID-19. METHODS: This retrospective analysis of the PCORnet Common Data Model across 4 academic medical centers through 1 September 2021 identified individuals age >50 years with a diagnosis of COVID-19. The composite outcome included ICU admission, ventilator use, or death within 15, 30, and 180 days of COVID-19 diagnosis. Use of N-BP was defined as a prescription within 3 years prior. ICU admission and ventilator use were determined using administrative codes. Death included both in-hospital and out-of-hospital events. Patients treated with N-BP were matched 1:1 by propensity score to patients without prior N-BP use. Secondary analysis compared outcomes among those prescribed zoledronic acid (ZOL) to those prescribed oral N-BPs. RESULTS: Of 76,223 COVID-19 patients identified, 1,853 were previously prescribed N-BP, among whom 559 were prescribed ZOL. After propensity score matching, there were no significant differences in the composite outcome at 15 days (HR 1.22, 95% CI: 0.89-1.67), 30 days (HR 1.24, 95% CI: 0.93-1.66), or 180 days (HR 1.17, 95% CI: 0.93-1.48), comparing those prescribed and not prescribed N-BP. Compared to those prescribed oral N-BP, there were no significant differences in outcomes among those prescribed ZOL. CONCLUSION: Among older COVID-19 patients, prior exposure to N-BP including ZOL was not associated with a reduction in ICU admission, ventilator use, or death.
引用
- Lee RH, Curtis J, Drake MT, et al. Association of prior treatment with nitrogen-containing bisphosphonates on outcomes of COVID-19 positive patients. Osteoporos Int. 2023. PMID: 37700010. doi:10.1007/s00198-023-06912-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。